Iovance Biotherapeutics, Inc. (IOVA)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Autologous Tumor Infiltrating Lymphocyte Cell Therapies	164.07M	Log In
Autologous Tumor Infiltrating Lymphocyte Cell Therapies Growth	13698.99%	Log In

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
United States	161.04M	Log In
United States Growth	13444.41%	Log In
Rest of World	3.03M	Log In